
Clariene SE (CLARI) | Financial Analysis & Statements
Clariene SE | Large-cap | Healthcare
Clariene SE | Large-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
14.3B
Total Liabilities
10.2B
Shareholders Equity
4.0B
Debt to Equity
2.55
Cash Flow Metrics
Revenue & Profitability Trend
Clariene SE Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 5.3B | 5.0B | 4.4B | 4.1B | 3.8B |
Cost of Goods Sold | 439.2M | 403.3M | 351.9M | 309.3M | 297.0M |
Gross Profit | 4.8B | 4.6B | 4.1B | 3.8B | 3.5B |
Gross Margin % | 91.7% | 91.9% | 92.1% | 92.5% | 92.1% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | 457.8M | 429.8M | 437.0M |
Other Operating Expenses | 632.6M | 612.7M | 510.9M | 473.5M | 503.8M |
Total Operating Expenses | 632.6M | 612.7M | 968.8M | 903.4M | 940.8M |
Operating Income | 287.3M | 255.6M | 334.5M | 403.3M | 180.9M |
Operating Margin % | 5.4% | 5.1% | 7.5% | 9.7% | 4.8% |
Non-Operating Items | |||||
Interest Income | 9.4M | - | - | 0 | 0 |
Interest Expense | 325.4M | 277.9M | 195.9M | 190.3M | 195.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -36.7M | -76.2M | 57.9M | 133.3M | 60.1M |
Income Tax | -9.4M | -2.6M | 12.2M | 11.4M | 17.2M |
Effective Tax Rate % | 0.0% | 0.0% | 21.0% | 8.6% | 28.6% |
Net Income | -51.7M | -93.1M | 31.3M | 112.9M | 42.1M |
Net Margin % | -1.0% | -1.9% | 0.7% | 2.7% | 1.1% |
Key Metrics | |||||
EBITDA | 1.1B | 993.9M | 979.4M | 1.0B | 835.6M |
EPS (Basic) | - | €-0.99 | €0.13 | €0.54 | €0.27 |
EPS (Diluted) | - | €-0.99 | €0.08 | €0.44 | €0.19 |
Basic Shares Outstanding | - | 106385000 | 168079333 | 168837783 | 147724642 |
Diluted Shares Outstanding | - | 106385000 | 168079333 | 168837783 | 147724642 |
Income Statement Trend
Clariene SE Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 518.1M | 677.9M | 733.7M | 1.2B | 1.2B |
Short-term Investments | 28.0K | 36.0K | 636.0K | 1.7M | 81.0K |
Accounts Receivable | 457.3M | 565.2M | 440.4M | 364.7M | 315.3M |
Inventory | 22.2M | 28.3M | 28.6M | 28.2M | 36.2M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 1.6B | 2.5B | 1.9B | 2.2B | 1.9B |
Non-Current Assets | |||||
Property, Plant & Equipment | 5.5B | 5.3B | 5.0B | 4.9B | 4.7B |
Goodwill | 8.8B | 8.9B | 8.7B | 8.6B | 8.0B |
Intangible Assets | 2.3B | 2.3B | 2.3B | 2.2B | 2.2B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | -1.0K | - | 2.0K | -1.0K |
Total Non-Current Assets | 12.6B | 12.7B | 12.7B | 12.1B | 11.3B |
Total Assets | 14.3B | 15.2B | 14.6B | 14.3B | 13.2B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 570.0M | 649.2M | 570.7M | 499.7M | 453.6M |
Short-term Debt | 1.4B | 1.5B | 1.3B | 1.0B | 1.3B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 143.3M | - | - | - | - |
Total Current Liabilities | 2.9B | 3.4B | 3.0B | 2.5B | 2.6B |
Non-Current Liabilities | |||||
Long-term Debt | 6.6B | 7.1B | 6.9B | 7.2B | 6.4B |
Deferred Tax Liabilities | 554.0M | 546.9M | 603.7M | 584.3M | 605.2M |
Other Non-Current Liabilities | 56.9M | 77.2M | 73.9M | 173.1M | 96.1M |
Total Non-Current Liabilities | 7.3B | 7.9B | 7.7B | 8.1B | 7.3B |
Total Liabilities | 10.2B | 11.2B | 10.7B | 10.5B | 9.9B |
Equity | |||||
Common Stock | 3.6M | 534.1M | 532.5M | 528.0M | 525.2M |
Retained Earnings | - | - | - | - | - |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 4.0B | 3.9B | 3.9B | 3.8B | 3.3B |
Key Metrics | |||||
Total Debt | 8.0B | 8.6B | 8.3B | 8.2B | 7.7B |
Working Capital | -1.3B | -887.4M | -1.0B | -245.2M | -731.5M |
Balance Sheet Composition
Clariene SE Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -26.9M | -80.3M | 45.0M | 121.7M | 42.1M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 61.5M | -155.5M | 30.9M | -147.9M | -16.9M |
Operating Cash Flow | 331.8M | 5.4M | 295.4M | 200.5M | 246.6M |
Investing Activities | |||||
Capital Expenditures | -308.0M | 57.3M | 95.9M | 7.6M | 27.2M |
Acquisitions | 292.5M | -265.4M | -245.7M | -307.6M | -610.6M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | 22.7M | 1.7M | 3.8M | 6.4M |
Investing Cash Flow | 57.8M | -185.4M | -148.1M | -288.5M | -549.8M |
Financing Activities | |||||
Share Repurchases | - | -493.0K | -6.5M | -2.6M | -1.2M |
Dividends Paid | -50.8M | -65.7M | -57.8M | -36.4M | -10.2M |
Debt Issuance | 142.0M | 1.1B | 811.1M | 1.8B | 1.9B |
Debt Repayment | -704.6M | -1.0B | -725.8M | -1.5B | -936.4M |
Financing Cash Flow | -393.9M | 350.5M | 22.7M | 608.9M | 1.6B |
Free Cash Flow | 600.1M | 309.1M | 239.5M | 311.1M | 274.7M |
Net Change in Cash | -4.4M | 170.5M | 170.0M | 520.9M | 1.3B |
Cash Flow Trend
Clariene SE Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
9.76
Forward P/E
54.65
Price to Book
0.43
Price to Sales
0.29
PEG Ratio
54.65
Profitability Ratios
Profit Margin
-1.16%
Operating Margin
3.80%
Return on Equity
-1.54%
Return on Assets
1.34%
Financial Health
Current Ratio
0.70
Debt to Equity
209.58
Beta
0.88
Per Share Data
EPS (TTM)
€-0.03
Book Value per Share
€10.08
Revenue per Share
€14.99
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
clari | 1.6B | 9.76 | 0.43 | -1.54% | -1.16% | 209.58 |
Emeis S.A | 2.1B | 0.02 | 1.20 | -23.02% | -7.31% | 514.45 |
Orpea | 2.0B | 0.10 | 0.85 | 704.66% | 26.07% | 485.11 |
Ramsay Générale de | 1.1B | 34.13 | 0.99 | -5.16% | -1.55% | 337.92 |
Lna Santé S.A | 286.3M | 13.10 | 0.91 | 7.25% | 2.71% | 270.87 |
EssilorLuxottica | 118.0B | 48.88 | 3.07 | 6.44% | 8.74% | 36.58 |
Financial data is updated regularly. All figures are in the company's reporting currency.